|  | Allo-HSCT (n = 47) | Chemotherapy or auto-HSCT (n = 18) | p-value |
---|---|---|---|---|
Age | median, (range) | 49 (19–70) | 59 (21–77) | 0.02 |
Sex | Male (%) | 30 (64) | 8 (44) | Â |
Female (%) | 17 (36) | 10 (56) | Â | |
Primary disease | AML | 22 (46.8) | 10 (55.6) | Â |
ALL | 9 (19.1) | 2 (11.1) | Â | |
MDS | 8 (17.0) | 1 (5.6) | Â | |
CML | 3 (6.4) | 0 (0.0) | Â | |
AA | 2 (4.3) | 1 (5.6) | Â | |
Aggressive NK leukemia | 1 (2.1) | 0 (0.0) | Â | |
NHL | 1 (2.1) | 0 (0.0) | Â | |
PMF | 1 (2.1) | 0 (0.0) | Â | |
Myeloma | 0 (0.0) | 3 (16.7) | Â | |
Creatinine (mg/dl) | median, (range) | 0.70 (0.3–3.0) | 0.60 (0.3–6.3) |  |
CRP (mg/dl) | median, (range) | 5.6 (0.3–40.8) | 5.6 (0.2–34.0) |  |
Albumin (g/dl) | median, (range) | 3.2 (1.6–4.2) | 2.9 (2.10–4.20) |  |
Neutropenia (%) | Â | 31 (66.0) | 13 (72.2) | Â |
 Profound neutropenia (%) |  | 21 (44.7) | 10 (55.6) |  |
 Duration of neutropenia (days) | median, (range) | 5.5 (0–30) | 4.5 (1–42) |  |
 Prolonged neutropenia (%) |  | 14 (29.8) | 6 (33.3) |  |
Initial source of infection (%) | Sources unknown | 26 (55.3) | 13 (72.2) | Â |
Cellulitis | 3 (6.4) | 1 (5.6) | Â | |
CLABSI | 13 (27.7) | 4 (22.2) | Â | |
Pneumonia | 5 (10.6) | 0 (0.0) | Â | |
Continuous bacteremia (%) | Â | 31 (66.0) | 7 (38.9) | Â |
Polymicrobial bacteremia (%) | Â | 19 (40.4) | 5 (27.8) | Â |
Severe sepsis or septic shock (%) | Â | 20 (42.6) | 3 (16.7) | Â |
Primary disease risk (%)a | High | 25 (53.2) | 9 (50.0) | Â |
Central venous catheter (%) | Â | 45 (95.7) | 11 (61.1) | <0.01 |
Mucositis (%) | Â | 20 (42.6) | 1 (5.6) | <0.01 |
Diarrhea (%) | Â | 26 (55.3) | 3 (16.7) | <0.01 |
Total parenteral nutrition (%)b | Â | 21 (44.7) | 1 (5.6) | <0.01 |
Administration of insulin (%)b | Â | 13 (27.7) | 0 (0.0) | 0.01 |
Urine catheter (%) | Â | 12 (25.5) | 1 (5.6) | Â |
Past history of broad-antibiotics (%)c | Â | 34 (72.3) | 14 (77.8) | Â |
Past history of carbapenem (%)c | Â | 24 (51.1) | 10 (55.6) | Â |
Decade | 2005 to 2009 (%) | 14 (29.8) | 6 (33.3) | Â |
2010 to 2014 (%) | 33 (70.2) | 12 (66.7) | Â | |
Time to appropriate therapy | median, (range) | 3 (0–30) |  |  |
Source of transplantation (%) | BM | 34 (72.3) | Â | Â |
PB | 7 (14.9) | Â | Â | |
CB | 6 (12.8) | Â | Â | |
Related or Unrelated donor (%) | Related donor | 10 (21.3) | Â | Â |
Unrelated donor | 37 (78.7) | Â | Â | |
HLA-matched donor (%) | Â | 22 (46.8) | Â | Â |
Conditioning intensity | Myeloablative | 33 (70.2) | Â | Â |
Reduced-intensity | 14 (29.8) | Â | Â | |
Acute GVHD (%)d | Â | 15 (31.9) | Â | Â |
 Grade (%) | I | 4 (26.7) |  |  |
II | 10 (66.7) | Â | Â | |
III | 1 (6.7) | Â | Â | |
 Manifestation of acute GVHDe | Skin | 14 (93.3) |  |  |
Gut | 4 (26.7) | Â | Â | |
Onset of bacteremia | During conditioning | 1 (2.1) | Â | Â |
Before engraftment | 31 (66.0) | Â | Â | |
After engraftment | 15 (31.9) | Â | Â | |
Days from transplantation (days) | median, (range) | 18 (−6–1434) |  |  |